LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.
The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch21
11:01 Why Yahoo CEO Marissa Mayer’s $141 Million Payday Is Safe From the Hack Cover-Up14
22:56 Yahoo says Verizon buyout delayed but still on20
22:53 LG Display reports record fourth quarter profit of $778 million17